These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 28273339

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D, Konno A.
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [Abstract] [Full Text] [Related]

  • 3. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J.
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [Abstract] [Full Text] [Related]

  • 4. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W, Hernández MD, Cardona V, Smeenk F, Fogh BS, Calderon MA, de Blay F, Backer V.
    Int Arch Allergy Immunol; 2017 Feb; 174(1):35-44. PubMed ID: 28950268
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [Abstract] [Full Text] [Related]

  • 6. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
    Bernstein DI, Kleine-Tebbe J, Nelson HS, Bardelas JA, Sussman GL, Lu S, Rehm D, Svanholm Fogh B, Nolte H.
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW, Han DH, Kim JW, Kim DY, Rhee CS.
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [Abstract] [Full Text] [Related]

  • 9. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, Ljørring C.
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [Abstract] [Full Text] [Related]

  • 10. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
    Klimek L, Mosbech H, Zieglmayer P, Rehm D, Stage BS, Demoly P.
    Expert Rev Clin Immunol; 2016 Feb; 12(4):369-77. PubMed ID: 26788764
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.
    JAMA; 2016 Apr 26; 315(16):1715-25. PubMed ID: 27115376
    [Abstract] [Full Text] [Related]

  • 12. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis.
    Demoly P, Okamoto Y, Yang WH, Devillier P, Bergmann KC.
    Expert Rev Clin Immunol; 2016 Nov 26; 12(11):1141-1151. PubMed ID: 27632814
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.
    Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K.
    Allergy; 2017 Mar 26; 72(3):435-443. PubMed ID: 27471838
    [Abstract] [Full Text] [Related]

  • 16. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
    Nolte H, Casale TB, Lockey RF, Fogh BS, Kaur A, Lu S, Nelson HS.
    J Allergy Clin Immunol Pract; 2017 Mar 26; 5(1):84-89.e3. PubMed ID: 27838323
    [Abstract] [Full Text] [Related]

  • 17. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, Kaur A, Zieglmayer P, Zieglmayer R, Lemell P, Horak F.
    J Allergy Clin Immunol; 2015 Jun 26; 135(6):1494-501.e6. PubMed ID: 25636947
    [Abstract] [Full Text] [Related]

  • 18. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
    Matsuoka T, Bernstein DI, Masuyama K, Nolte H, Okamiya K, Seitzberg D, Nelson HS.
    Pediatr Allergy Immunol; 2017 Nov 26; 28(7):661-667. PubMed ID: 28660739
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
    Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, Ohashi-Doi K, Natsui K, Imai T, Okubo K.
    Allergy; 2018 Dec 26; 73(12):2352-2363. PubMed ID: 30043449
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.
    Okamoto Y, Fujieda S, Okano M, Hida H, Kakudo S, Masuyama K.
    Pediatr Allergy Immunol; 2019 Feb 26; 30(1):66-73. PubMed ID: 30281866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.